Rituximab plus chemotherapy in follicular and mantle cell lymphomas-Reference-Cited by-同舟云学术

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

Published:2003-02 Issue:1 Volume:30 Page:16-20
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Hiddemann Wolfgang,Dreyling Martin,Unterhalt Michael

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference27 articles.

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998

2. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab;Davis;J Clin Oncol,1999

3. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment;Davis;J Clin Oncol,2000

4. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group;Feuring-Buske;Ann Hematol,2000

5. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan;Tobinai;Cancer Chemother Pharmacol,2001

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology to Practice;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Imaging Assessment of Tumor Response in the Era of Immunotherapy;Diagnostics;2021-06-05

3. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions;Journal of Clinical Medicine;2021-03-14

4. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma;Human Pathology;2019-11

5. Front‐line management of non‐Hodgkin lymphoma in Australia. Part 1: follicular lymphoma;Internal Medicine Journal;2019-04